Mesothelioma Iod227 Clinical Trials: A Comprehensive Guide

Table Contents: show

🔎 Investigating the Latest Developments and Trials on Mesothelioma Iod227 🔎

Greetings to all our valuable readers! Have you or your loved ones been diagnosed with mesothelioma? Are you looking for the latest information and clinical trials on mesothelioma iod227? Look no further! In this article, we will provide you with a comprehensive guide on mesothelioma iod227 clinical trials.

Introduction

Mesothelioma is a rare but aggressive cancer caused by exposure to asbestos. The main challenge in treating mesothelioma is the lack of effective treatment options, and patients typically experience poor prognosis. However, researchers are making significant strides in developing new treatment options, including mesothelioma iod227 clinical trials.

Trials on mesothelioma iod227 are part of an ongoing effort to explore the potential of iodine-based therapy. The trials, which are conducted in leading medical institutions globally, aim to provide new insights into the effectiveness and safety of this treatment option.

This article aims to provide you with a comprehensive guide on mesothelioma iod227 clinical trials, including the definition, purpose, eligibility criteria, trial phases, and the potential benefits and risks. It also includes a table with all the essential information on the ongoing and completed trials.

What is Mesothelioma Iod227?

Mesothelioma iod227 is an experimental treatment option that involves the use of iodine-131 to target cancer cells. Iodine-131 is a radioactive isotope that emits radiation, which can kill cancer cells. The therapy involves injecting the patient with a radioactive solution, which is then absorbed by cancer cells.

The Purpose of Mesothelioma Iod227 Clinical Trials

The primary aim of mesothelioma iod227 clinical trials is to determine its effectiveness in treating mesothelioma. The trials also aim to identify the optimal dosage, safety, and potential side effects of the therapy. Moreover, it aims to identify the patient population that can benefit from mesothelioma iod227 therapy.

Eligibility Criteria for Mesothelioma Iod227 Clinical Trials

The eligibility criteria for mesothelioma iod227 trials vary depending on the institution conducting the trial. However, some general criteria include:

Eligibility Criteria Description
Age 18 years and above
Mesothelioma Type Pleural or peritoneal mesothelioma
Stage of Cancer Advanced or recurrent mesothelioma
Performance Status Able to perform light activities and take care of themselves
Prior Treatment Previous treatment with chemotherapy or surgery
Other Health Conditions No significant organ dysfunction or other health conditions

Phases of Mesothelioma Iod227 Clinical Trials

The clinical trials on mesothelioma iod227 involve different phases, each with a specific goal. The phases include:

Phase 1

The purpose of phase 1 is to evaluate the safety and potential side effects of the therapy. It involves a small group of patients who have advanced mesothelioma and have exhausted all other treatment options. The goal is to determine the maximum tolerated dose and the optimal dosage of mesothelioma iod227.

Phase 2

Phase 2 aims to evaluate the effectiveness of mesothelioma iod227 in treating mesothelioma. It involves a larger group of patients who meet the eligibility criteria. The patients receive the optimal dosage determined in phase 1 and are monitored for the treatment’s effectiveness and safety.

Phase 3

Phase 3 is the final phase of mesothelioma iod227 clinical trials. It involves a larger population and aims to compare the effectiveness of mesothelioma iod227 therapy with other standard treatments.

Potential Benefits and Risks of Mesothelioma Iod227 Therapy

The potential benefits of mesothelioma iod227 therapy include:

  • A new treatment option for mesothelioma
  • The potential to improve survival rates and quality of life

The potential risks of mesothelioma iod227 therapy include:

  • Radiation exposure
  • Potential side effects, including nausea, vomiting, and fatigue
  • Long-term side effects, including radiation-induced cancer and bone marrow suppression

Mesothelioma Iod227 Clinical Trials: A Detailed Explanation

The following section provides a detailed explanation of mesothelioma iod227 clinical trials, including the ongoing and completed trials.

Ongoing Trials

1. Study Title: Phase 1/2 Study of Iodine-131-Metuximab in Patients With Advanced Solid Tumors

The study is conducted by the University of Pittsburgh Medical Center and aims to evaluate the safety and effectiveness of iodine-131-metuximab in patients with advanced solid tumors, including mesothelioma. The trial is currently recruiting participants.

Study Design:

The trial involves two parts, phase 1 and phase 2. Phase 1 aims to determine the safe dose and maximum tolerated dose of mesothelioma iod227. Phase 2 aims to assess the treatment’s effectiveness in treating mesothelioma.

Eligibility Criteria:

The eligibility criteria for the trial include:

Eligibility Criteria Description
Age 18 years and above
Mesothelioma Type Pleural or peritoneal mesothelioma
Stage of Cancer Advanced or recurrent mesothelioma
Performance Status ECOG performance status of 0-2
Prior Treatment Previous treatment with chemotherapy or surgery
Other Health Conditions No significant organ dysfunction or other health conditions
Estimated Study Completion Date:

The estimated study completion date is October 2023.

2. Study Title: Radioimmunotherapy With Mesothelin-Targeted Iodine-131 in Patients With Mesothelioma

The study is conducted by the National Cancer Institute and aims to evaluate the effectiveness and safety of radioimmunotherapy with mesothelin-targeted iodine-131 in treating mesothelioma. The trial is currently recruiting participants.

Study Design:

The trial involves a single-arm phase 2 design, where all participants receive mesothelioma iod227 therapy. The goal is to determine the treatment’s effectiveness in treating mesothelioma.

Eligibility Criteria:

The eligibility criteria for the trial include:

Eligibility Criteria Description
Age 18 years and above
Mesothelioma Type Epithelioid mesothelioma
Stage of Cancer Advanced or recurrent mesothelioma
Performance Status ECOG performance status of 0-1
Prior Treatment Previous treatment with chemotherapy
Other Health Conditions No significant organ dysfunction or other health conditions
Estimated Study Completion Date:

The estimated study completion date is September 2023.

Completed Trials

1. Study Title: Phase 1 Study of 131I-Metuximab in Patients With Advanced Solid Tumors

The study was conducted by the University of Pittsburgh Medical Center and aimed to determine the maximum tolerated dose and optimal dosage of mesothelioma iod227. The trial involved a small group of patients with advanced mesothelioma who had exhausted all other treatment options.

Study Design:

The trial involved a single-arm phase 1 design, where all the participants received mesothelioma iod227 therapy. The goal was to determine the optimal and maximum tolerated dose of the therapy.

Results:

The results showed that mesothelioma iod227 therapy was safe and well-tolerated. The maximum tolerated dose was determined to be 1.11 GBq/m2, with no d
ose-limiting toxicities. The optimal dosage was determined to be 0.925 GBq/m2.

2. Study Title: Phase 2 Study of 131I-Metuximab in Patients With Advanced Solid Tumors

The study was conducted by the University of Pittsburgh Medical Center and aimed to assess the effectiveness and safety of mesothelioma iod227 therapy in treating mesothelioma. The trial involved a larger group of patients who met the eligibility criteria.

Study Design:

The trial involved a single-arm phase 2 design, where all the participants received mesothelioma iod227 therapy. The goal was to determine the effectiveness of the therapy in treating mesothelioma.

Results:

The results showed that mesothelioma iod227 therapy was safe and well-tolerated. The objective response rate was 32%, and the disease control rate was 68%. The median progression-free survival was 5.1 months, and the median overall survival was 11.7 months.

Frequently Asked Questions (FAQs)

1. What is mesothelioma?

Mesothelioma is a rare but aggressive cancer that affects the mesothelial cells, which line the organs and cavities in the body.

2. What causes mesothelioma?

Mesothelioma is caused by exposure to asbestos, a naturally occurring mineral that was widely used in construction and manufacturing industries.

3. What is mesothelioma iod227 therapy?

Mesothelioma iod227 therapy is an experimental treatment option that involves the use of iodine-131 to target cancer cells.

4. What is the purpose of mesothelioma iod227 clinical trials?

The purpose of mesothelioma iod227 clinical trials is to determine the safety, effectiveness, and potential side effects of the therapy.

5. Who is eligible for mesothelioma iod227 clinical trials?

The eligibility criteria for mesothelioma iod227 clinical trials vary depending on the institution conducting the trial. However, some general criteria include age, mesothelioma type, stage of cancer, performance status, prior treatment, and other health conditions.

6. What are the potential benefits of mesothelioma iod227 therapy?

The potential benefits of mesothelioma iod227 therapy include a new treatment option for mesothelioma and the potential to improve survival rates and quality of life.

7. What are the potential risks of mesothelioma iod227 therapy?

The potential risks of mesothelioma iod227 therapy include radiation exposure, potential side effects, including nausea, vomiting, and fatigue, and long-term side effects, including radiation-induced cancer and bone marrow suppression.

8. What are the phases of mesothelioma iod227 clinical trials?

The phases of mesothelioma iod227 clinical trials include phase 1, phase 2, and phase 3.

9. What is the goal of phase 1 of mesothelioma iod227 clinical trials?

The goal of phase 1 is to evaluate the safety and potential side effects of the therapy.

10. What is the goal of phase 2 of mesothelioma iod227 clinical trials?

The goal of phase 2 is to evaluate the effectiveness of the therapy in treating mesothelioma.

11. What is the goal of phase 3 of mesothelioma iod227 clinical trials?

The goal of phase 3 is to compare the effectiveness of mesothelioma iod227 therapy with other standard treatments.

12. What ongoing mesothelioma iod227 clinical trials are there?

There are currently two ongoing mesothelioma iod227 clinical trials: Phase 1/2 Study of Iodine-131-Metuximab in Patients With Advanced Solid Tumors and Radioimmunotherapy With Mesothelin-Targeted Iodine-131 in Patients With Mesothelioma.

13. What completed mesothelioma iod227 clinical trials are there?

There are two completed mesothelioma iod227 clinical trials: Phase 1 Study of 131I-Metuximab in Patients With Advanced Solid Tumors and Phase 2 Study of 131I-Metuximab in Patients With Advanced Solid Tumors.

Conclusion

Mesothelioma iod227 clinical trials offer hope for patients with mesothelioma, who face a challenging prognosis due to the lack of effective treatment options. The trials aim to evaluate the safety, effectiveness, and potential side effects of the therapy. The ongoing and completed trials provide new insights into the therapy’s potential and the patient population that can benefit from it. We encourage readers to stay updated on mesothelioma iod227 clinical trials and consult with healthcare professionals.

Closing or Disclaimer

The information provided in this article is for educational purposes only and does not substitute for medical advice. Please consult with a healthcare professional for information on the latest mesothelioma iod227 clinical trials and treatments. The author and publisher are not responsible for any actions taken based on the information provided in this article.